Sara Patel is an associate in the London office of Latham & Watkins and advises healthcare, life sciences, and technology companies and their investors on a range of intellectual property, regulatory, and complex commercial matters, with a particular focus on cross border transactions. She advises clients at all stages from emerging companies to global market leaders, in sectors including:

  • Pharmaceutical and biotechnology
  • Medical devices
  • Digital health and AI
  • Cosmetics

She advises clients on transactional and regulatory matters, including:

  • Strategic licensing and collaborations
  • Manufacturing, supply, and distribution agreements
  • Life sciences and AI regulatory
  • Research and development agreements
  • Joint ventures
  • Mergers and acquisitions
  • IPOs and follow-on offerings
  • Regulatory compliance

Prior to joining Latham, Ms. Patel also worked as in-house counsel at Gilead Sciences in its EMEA HQ for five years, including time in Gilead’s Silicon Valley and UAE offices. She has a degree in Biological Sciences and draws on her life sciences industry background and business perspective to her legal representations.

Ms. Patel also maintains an active pro bono practice in relation to intellectual property, commercial and regulatory matters. She currently serves as the London Office Leader of the Asian and Middle Eastern Lawyers Group.

Thought Leadership

A recognized thought leader, Ms. Patel regularly speaks and writes on healthcare, life sciences, and digital health related topics. Ms. Patel's recent publications in industry journals and speaking engagements include:

Ms. Patel’s experience includes advising:

Strategic Intellectual Property Transactions

  • CollPlant Biotechnologies, a regenerative medicine company, in a worldwide exclusive development and commercialization agreement for dermal and soft tissue filler products with Allergan Aesthetics, an AbbVie company
  • A leading medical technology company on a strategic license agreement for the development and commercialization of its medical technology platform
  • GSK on variety of matters including supply arrangements
  • A world-leading state-of-the-art GCC hospital in relation to agreements for the global supply of medicinal product and medical devices
  • A UK-based DNA/RNA sequencing company on a variety of intellectual property and complex commercial agreements*
  • A Jordan-based pharmaceutical company in relation to its strategic license and distribution agreements*

Joint Ventures and M&A

  • Norgine, a Netherlands-based specialty pharmaceutical company on regulatory matters in its US$2 billion sale to Goldman Sachs
  • A multinational world-leading pharmaceutical company on intellectual property, commercial and regulatory matters in its US$1.5 billion acquisition of a UK biotech company
  • Astorg on its binding agreement to acquire CordenPharma, a leading pharmaceutical contract development and manufacturing organization, from ICIG, a privately owned industrial group
  • Silver Lake Partners on its €3.5 billion investment in IVC Evidensia, a leading European veterinary care provider
  • Novo Holdings on leading a Series D funding round for Quanta Dialysis Technologies, a medical technology leader delivering on its vision for more flexible and accessible dialysis care and acquisition of BBI Group, a leading supplier of products and services to the global diagnostics and life sciences industries
  • Nordic Capital in its US$846 million acquisition of Advanz Pharma, a UK-based specialty pharmaceutical company
  • A global medical device company on its joint venture with a world-leading multinational company for the manufacture and distribution of spectacle lenses
  • Owens & Minor, Inc. a global healthcare solutions company on the sale of its European logistics business, Movianto, to EHDH Holding Group*
  • CBPE Capital on its acquisition of Simbec-Orion, an international CRO*
  • A leading Middle Eastern pharmaceutical company on its JV with an Indian generics company*


  • A leading European pharmaceutical industry association on strategic legal and policy analyses of the EU framework regulating innovation in pharmaceutical product development
  • Various pharmaceutical and medical technology companies regarding pharmacovigilance, clinical trials and other study agreements
  • Various global pharmaceutical clients in relation to their regulatory compliance programs and interactions with HCPs*
  • A global social media platform in connection with its medical device product launch in the UAE
  • A leading Germany-based medical device company in connection with the supply and distribution of medical devices in the UAE
  • Amplifon SpA in connection with its medical device product launch in the UK and EU* 
  • A US pharmaceutical company in relation to product launch and the supply of medicinal product to the UAE, Kuwait, and Qatar*
  • A range of medical device and technology companies in relation to product launches for COVID-19 diagnostic tests*

*Matter handled prior to joining Latham 

Bar Qualification

  • England and Wales (Solicitor)


  • Graduate Diploma in Law and Legal Practice Course, BPP Law School, London
  • B.Sc., Warwick University
    First Class Honours

Languages Spoken

  • English
  • Urdu
  • Hindi